An open-label, randomized, 4-treatment, 3-period, crossover interaction study, evaluating the effect of esomeprazole 40 mg, omeprazole 80 mg or lansoprazole 60 mg on the pharmacodynamics and the pharmacokinetics of clopidogrel in healthy volunteers

Trial Profile

An open-label, randomized, 4-treatment, 3-period, crossover interaction study, evaluating the effect of esomeprazole 40 mg, omeprazole 80 mg or lansoprazole 60 mg on the pharmacodynamics and the pharmacokinetics of clopidogrel in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Esomeprazole (Primary) ; Lansoprazole (Primary) ; Omeprazole (Primary) ; Clopidogrel
  • Indications Bleeding ulcer; Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Mar 2014 Results published in the American Journal of Cardiovascular Drugs.
    • 27 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 27 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top